v3.25.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Common Stock
Additional Paid-in Capital.
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Total
Balance at the beginning of the period (in shares) at Dec. 31, 2023 25,565,414        
Balance at the beginning of the period at Dec. 31, 2023 $ 26 $ 459,591 $ 106 $ (399,582) $ 60,141
Increase (Decrease) in Stockholders' Equity          
Issuance of common stock upon vest of restricted stock units (in shares) 27,500        
Issuance of common stock upon exercise of stock options   29     29
Issuance of common stock upon exercise of stock options (in shares) 10,557        
April 2024 Private Placement (net of issuance costs of $2,948) $ 12 37,039     37,051
April 2024 Private Placement (net of issuance costs of $2,948) (in shares) 12,660,993        
Dividend attributable to the down round feature of 2017 Warrants   234   (234)  
Foreign currency translation adjustment     (103)   (103)
Stock-based compensation   2,618     2,618
Net loss       (33,948) (33,948)
Balance at the end of the period at Jun. 30, 2024 $ 38 499,511 3 (433,764) 65,788
Balance at the end of the period (in shares) at Jun. 30, 2024 38,264,464        
Balance at the beginning of the period (in shares) at Mar. 31, 2024 25,603,471        
Balance at the beginning of the period at Mar. 31, 2024 $ 26 460,868 (120) (413,402) 47,372
Increase (Decrease) in Stockholders' Equity          
April 2024 Private Placement (net of issuance costs of $2,948) $ 12 37,039     37,051
April 2024 Private Placement (net of issuance costs of $2,948) (in shares) 12,660,993        
Dividend attributable to the down round feature of 2017 Warrants   234   (234)  
Foreign currency translation adjustment     123   123
Stock-based compensation   1,370     1,370
Net loss       (20,128) (20,128)
Balance at the end of the period at Jun. 30, 2024 $ 38 499,511 3 (433,764) 65,788
Balance at the end of the period (in shares) at Jun. 30, 2024 38,264,464        
Balance at the beginning of the period (in shares) at Dec. 31, 2024 38,329,894        
Balance at the beginning of the period at Dec. 31, 2024 $ 38 502,501 (120) (467,371) 35,048
Increase (Decrease) in Stockholders' Equity          
Issuance of common stock upon vest of restricted stock units (in shares) 181,927        
Issuance of common stock upon exercise of prefunded warrants $ 3 (3)      
Issuance of common stock upon exercise of prefunded warrants (in shares) 2,921,041        
Issuance of common stock upon exercise of stock options   16     $ 16
Issuance of common stock upon exercise of stock options (in shares) 6,667       6,667
Foreign currency translation adjustment     38   $ 38
Stock-based compensation   2,693     2,067
Net loss       (32,078) (32,078)
Balance at the end of the period at Jun. 30, 2025 $ 41 505,207 (82) (499,449) 5,717
Balance at the end of the period (in shares) at Jun. 30, 2025 41,439,529        
Balance at the beginning of the period (in shares) at Mar. 31, 2025 41,439,529        
Balance at the beginning of the period at Mar. 31, 2025 $ 41 503,718 (113) (482,806) 20,840
Increase (Decrease) in Stockholders' Equity          
Foreign currency translation adjustment     31   31
Stock-based compensation   1,489     863
Net loss       (16,643) (16,643)
Balance at the end of the period at Jun. 30, 2025 $ 41 $ 505,207 $ (82) $ (499,449) $ 5,717
Balance at the end of the period (in shares) at Jun. 30, 2025 41,439,529